05 — Disabled macroautophagy
Primary hallmark ("damage"), added as a hallmark in its own right in López-Otín et al., Cell 2023 (doi:10.1016/j.cell.2022.11.001); in 2013 it was included in loss of proteostasis (file 04).
1. Definition
Age-related decline of macroautophagy: the process by which the cell encloses portions of its contents (aggregated proteins, worn-out organelles such as mitochondria, lipid droplets, microbes) in a double-membrane vesicle (the autophagosome) and then delivers them to the lysosome to be digested and recycled. Its activity falls with age in most tissues; blocking it genetically accelerates degeneration and activating it extends life in several animal species (Aman 2021, doi:10.1038/s43587-021-00098-4; Rubinsztein 2011, doi:10.1016/j.cell.2011.07.030).
In plain terms: autophagy ("self-eating") is the cell's sorting and recycling service. It packs waste and worn-out parts into a bag and takes them to the recycling plant (the lysosome), which cuts them into reusable materials. With age, the trucks come less often and the plant runs slowly: waste builds up.
2. Mechanisms and sources
Normal operation
- Triggering: the nutrient sensor mTORC1 slows autophagy when food is plentiful; AMPK (an energy sensor) activates it when energy is short. Fasting, exercise and mTOR inhibition stimulate it.
- Building the autophagosome: about thirty ATG genes (ULK1 complex, Beclin 1-VPS34 complex, ATG5-ATG12-ATG16L1 conjugation, LC3).
- Fusion with the lysosome and digestion: requires functional lysosomes, whose production is driven by the transcription factor TFEB (Settembre 2011, doi:10.1126/science.1204592).
- Selective forms: mitophagy (mitochondria), aggrephagy (aggregates), lipophagy (fats), xenophagy (microbes).
What degrades with age (Hansen 2018, doi:10.1038/s41580-018-0033-y)
- Lower expression of ATG genes and TFEB in several tissues.
- Rubicon, a brake on autophagosome-lysosome fusion, increases with age in the worm, the fly and the mouse; removing it extends the life of the worm and the fly and reduces kidney fibrosis in mice (Nakamura 2019, doi:10.1038/s41467-019-08729-6).
- Lysosomes clogged with lipofuscin ("age pigment"), less acidic, less efficient.
- Chronic overactivation of mTORC1 (excess nutrients, insulin).
Causal evidence in animals
- Necessary: in the worm, long-lived mutants (insulin pathway, caloric restriction) lose their longevity if autophagy is blocked (Meléndez 2003, doi:10.1126/science.1087782; review: Madeo 2015, doi:10.1172/JCI73946).
- Harmful when absent: deleting Atg5 or Atg7 in mouse neurons leads to aggregates and neurodegeneration, even without a mutant protein (Hara 2006, doi:10.1038/nature04724; Komatsu 2006, doi:10.1038/nature04723).
- Sufficient: overexpressing Atg5 (Pyo 2013, doi:10.1038/ncomms3300) or making Beclin 1 constitutively active (Fernández 2018, doi:10.1038/s41586-018-0162-7) extends mouse lifespan and delays age-related pathologies.
3. Symptoms and clinical manifestations
Human genetics: mutations in autophagy genes cause or promote diseases (review: Levine & Kroemer 2019, doi:10.1016/j.cell.2018.09.048):
- Crohn's disease: ATG16L1 T300A variant identified by GWAS (Hampe 2006, doi:10.1038/ng1954).
- Parkinson's disease: PINK1 and PRKN (Parkin), mitophagy genes, cause familial forms.
- ALS / frontotemporal dementia: mutations in autophagy receptors (SQSTM1/p62, OPTN, TBK1).
- Lysosomal diseases (Niemann-Pick, Gaucher…): the recycling plant is broken; GBA mutations = major risk factor for Parkinson's.
- EPG5 and WDR45 mutations: severe neurodevelopmental and neurodegenerative diseases.
Associated age-related diseases: neurodegeneration (Alzheimer's, Parkinson's, Huntington's), sarcopenia (muscle wasting), heart failure, hepatic steatosis (fatty liver), type 2 diabetes, infections, some cancers (ambivalent role: autophagy slows the appearance of tumours but helps established tumours survive).
Mitophagy and the brain: in mouse models of Alzheimer's, stimulating mitophagy reduces amyloid-β and tau and restores memory (Fang 2019, doi:10.1038/s41593-018-0332-9).
4. Interactions with the other hallmarks
| Hallmark (2023 numbering) | Link with disabled macroautophagy |
|---|---|
| 1. Genomic instability | Autophagy clears micronuclei and mitochondria that produce free radicals; its decline increases DNA damage. |
| 2. Telomere attrition | Indirect link (senescence, oxidative stress). |
| 3. Epigenetic alterations | Expression of ATG genes and TFEB is epigenetically regulated; spermidine induces autophagy by inhibiting the acetyltransferase EP300 (Pietrocola 2015, doi:10.1038/cdd.2014.215). |
| 4. Loss of proteostasis | The two hallmarks overlap: macroautophagy is the only route able to clear large aggregates (file 04). |
| 6. Deregulated nutrient sensing | mTORC1 (brake) and AMPK (accelerator) are the main switches; most longevity interventions (caloric restriction, rapamycin) work through autophagy (Madeo 2015). |
| 7. Mitochondrial dysfunction | Mitophagy clears defective mitochondria; its decline lets them accumulate. |
| 8. Cellular senescence | Ambivalent role: autophagy prevents senescence but also contributes to producing the senescent secretome. |
| 9. Stem cell exhaustion | In mice, old muscle stem cells lose their autophagy, which tips them into senescence (García-Prat 2016, doi:10.1038/nature16187); blood stem cells need autophagy to stay quiescent and functional (Ho 2017, doi:10.1038/nature21388). |
| 10. Altered intercellular communication | Autophagy-dependent unconventional secretion of proteins and vesicles. |
| 11. Chronic inflammation | Autophagy restrains the NLRP3 inflammasome; its decline promotes "inflammaging". |
| 12. Dysbiosis | Xenophagy: defence against gut bacteria (Crohn's/ATG16L1 link). The microbiota produces autophagy inducers (urolithin A, spermidine). |
5. Existing or investigational remedies
| Intervention | Target | Level of evidence | Key result | Source |
|---|---|---|---|---|
| Rapamycin | Inhibits mTORC1 → activates autophagy | Solid preclinical; human phase 2 trials | Extends mouse lifespan even when started late (Harrison 2009); an analogue (everolimus) improves the vaccine response of older people (Mannick 2014); TORC1 inhibition reduces infections (Mannick 2018). PEARL trial (1 year, low doses): well tolerated, modest effects on some markers (Moel 2025). | doi:10.1038/nature08221; doi:10.1126/scitranslmed.3009892; doi:10.1126/scitranslmed.aaq1564; doi:10.18632/aging.206235; review Mannick 2021 doi:10.1016/S2666-7568(21)00062-3 |
| Spermidine | Natural autophagy inducer | Preclinical; human observational; human randomised trial | Extends the life of yeast, worm and fly (Eisenberg 2009) and protects the mouse heart (Eisenberg 2016). High dietary intake associated with lower mortality (Bruneck cohort, Kiechl 2018). SmartAge trial (12 months, 100 older adults): no effect on memory (Schwarz 2022). | doi:10.1038/ncb1975; doi:10.1038/nm.4222; doi:10.1093/ajcn/nqy102; doi:10.1001/jamanetworkopen.2022.13875 |
| Urolithin A (microbial metabolite of pomegranate ellagitannins) | Mitophagy | Preclinical; human phase 1-2 trials | Extends worm life, improves mouse muscle (Ryu 2016); safe, with a mitochondrial signature in humans (Andreux 2019); 4-month trial in 66 older adults: no improvement in the primary endpoint (walking distance), gains in muscle endurance (Liu 2022). | doi:10.1038/nm.4132; doi:10.1038/s42255-019-0073-4; doi:10.1001/jamanetworkopen.2021.44279 |
| Intermittent fasting / caloric restriction | mTOR ↓, AMPK ↑ | Solid preclinical; human trials (metabolic markers) | Cardiometabolic benefits in humans; autophagy induction hard to measure directly | de Cabo & Mattson 2019, doi:10.1056/NEJMra1905136 |
| Physical exercise | Muscle autophagy (via BCL2-Beclin 1) | Preclinical (mechanism); established clinical benefits | In mice, exercise-induced autophagy is required for some metabolic benefits | He 2012, doi:10.1038/nature10758 |
| Genetic activation (Atg5, Beclin 1 F121A, Rubicon deletion) | Autophagy machinery | Preclinical | Lifespan extension in the mouse or the worm | Pyo 2013; Fernández 2018; Nakamura 2019 |
| Stimulating mitophagy (NAD+, urolithin A) | Mitochondria | Preclinical (Alzheimer's models) | Reduces amyloid and tau, improves memory | Fang 2019 |
Finding: rapamycin is the strongest candidate in animals; in humans, the data concern markers (immunity, infections) in small samples. Supplements (spermidine, urolithin A) have modest or negative human results on their primary endpoints. There is no reliable measure of autophagy in a living person.
6. Open questions
- Measurement: how to quantify autophagic flux in humans (blood, biopsy)? Without a biomarker, an intervention cannot be dosed.
- Specificity: can selective autophagy (mitophagy in muscle, aggrephagy in neurons) be activated rather than a global effect?
- Cancer: activating autophagy can help an existing tumour survive; which patient profile?
- Rapamycin in humans: what dose and schedule (intermittent) target mTORC1 without the side effects linked to mTORC2 (hyperglycaemia, immunosuppression)?
- The lysosome as the weak link: stimulating autophagy is useless if the lysosome is saturated; is TFEB a better target?
7. References
- López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023. doi:10.1016/j.cell.2022.11.001
- Aman Y, et al. Autophagy in healthy aging and disease. Nat Aging 2021. doi:10.1038/s43587-021-00098-4
- Rubinsztein DC, Mariño G, Kroemer G. Autophagy and aging. Cell 2011. doi:10.1016/j.cell.2011.07.030
- Hansen M, Rubinsztein DC, Walker DW. Autophagy as a promoter of longevity: insights from model organisms. Nat Rev Mol Cell Biol 2018. doi:10.1038/s41580-018-0033-y
- Madeo F, Zimmermann A, Maiuri MC, Kroemer G. Essential role for autophagy in life span extension. J Clin Invest 2015. doi:10.1172/JCI73946
- Levine B, Kroemer G. Biological functions of autophagy genes: a disease perspective. Cell 2019. doi:10.1016/j.cell.2018.09.048
- Settembre C, et al. TFEB links autophagy to lysosomal biogenesis. Science 2011. doi:10.1126/science.1204592
- Nakamura S, et al. Suppression of autophagic activity by Rubicon is a signature of aging. Nat Commun 2019. doi:10.1038/s41467-019-08729-6
- Meléndez A, et al. Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science 2003. doi:10.1126/science.1087782
- Hara T, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006. doi:10.1038/nature04724
- Komatsu M, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006. doi:10.1038/nature04723
- Pyo JO, et al. Overexpression of Atg5 in mice activates autophagy and extends lifespan. Nat Commun 2013. doi:10.1038/ncomms3300
- Fernández ÁF, et al. Disruption of the beclin 1–BCL2 autophagy regulatory complex promotes longevity in mice. Nature 2018. doi:10.1038/s41586-018-0162-7
- Hampe J, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2006. doi:10.1038/ng1954
- Fang EF, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci 2019. doi:10.1038/s41593-018-0332-9
- Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009. doi:10.1038/nature08221
- Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014. doi:10.1126/scitranslmed.3009892
- Mannick JB, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 2018. doi:10.1126/scitranslmed.aaq1564
- Mannick JB, Lamming DW. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults. Lancet Healthy Longev 2021. doi:10.1016/S2666-7568(21)00062-3
- Moel M, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging 2025. doi:10.18632/aging.206235
- Eisenberg T, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 2009. doi:10.1038/ncb1975
- Eisenberg T, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med 2016. doi:10.1038/nm.4222
- Kiechl S, et al. Higher spermidine intake is linked to lower mortality: a prospective population-based study. Am J Clin Nutr 2018. doi:10.1093/ajcn/nqy102
- Schwarz C, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: a randomized clinical trial. JAMA Netw Open 2022. doi:10.1001/jamanetworkopen.2022.13875
- Ryu D, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med 2016. doi:10.1038/nm.4132
- Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab 2019. doi:10.1038/s42255-019-0073-4
- Liu S, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Netw Open 2022. doi:10.1001/jamanetworkopen.2021.44279
- de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. NEJM 2019. doi:10.1056/NEJMra1905136
- He C, et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012. doi:10.1038/nature10758
- Pietrocola F, et al. Spermidine induces autophagy by inhibiting the acetyltransferase EP300. Cell Death Differ 2015. doi:10.1038/cdd.2014.215
- García-Prat L, et al. Autophagy maintains stemness by preventing senescence. Nature 2016. doi:10.1038/nature16187
- Ho TT, et al. Autophagy maintains the metabolism and function of young and old stem cells. Nature 2017. doi:10.1038/nature21388
DOIs verified via the Crossref API on 2026-10-19.